Ran Salomon
Associate Director, Antibody Engineering at Compugen | Israel
Ran Salomon’s Email & Phone Number
VerifiedFree account · No credit card · 5 profiles/month
Associate Director, Antibody Engineering at Compugen in April 2025 - Present
Principal Scientist at Compugen in June 2024 - March 2025
Senior Scientist at Immunai in September 2022 - August 2024
Academic Affairs and Networks Project Leader at Teva Pharmaceuticals in February 2022 - September 2022
Senior Research Associate at Compugen in January 2014 - November 2017
Associate Researcher at Teva Pharmaceuticals in October 2010 - October 2011
Weizmann Institute of Science, Doctor of Philosophy - PhD, June 2026
Weizmann Institute of Science, Master of Science - MS, June 2026
Tel Aviv University, Bachelor of Science - BS, June 2026
About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable AI/ML powered computational discovery platform (Unigen™) to identify novel drug targets and biological pathways for developing cancer immunotherapies. Compugen has two differentiated Fc-reduced programs targeting TIGIT: COM902, a fully owned potential best-in-class Fc-reduced high affinity anti-TIGIT antibody in Phase 1 development and rilvegostomig, an Fc-reduced PD-1/TIGIT bispecific antibody in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. The TIGIT component of rilvegostomig is derived from COM902. In Phase 1 development Compugen has COM701, a potential first-in-class anti-PVRIG Fc-reduced antibody and GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen's offices are located in Israel. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN
Discover more about Compugen
Director, Research & Drug Discovery at Compugen
Director at Compugen
(April 2022 – Present)
Director, Biostatistics and Programming at Compugen
Director, Biostatistics and Programming at Compugen
(Apr 2025 – Present)
Executive Chair of Board of Directors at Compugen
Board Member at Compugen
(Sep 2014 – Present)
Senior Vice President, Business Development at Compugen Ltd.
Senior Vice President, Technology Innovation at Compugen Ltd.
(Oct 2018 – Present)
SVP Research & Discovery at Compugen | Drug Discovery | Venture Creation | AI in Pharma
Scientific Advisory Board, Colton Multidisciplinary Center for Autoimmunity Research at Tel Aviv University
(Apr 2024 – Present)
Senior Director, Drug safety & Pharmacovigilance at Compugen
Senior Director of Drug Safety & Pharmacovigilance at Compugen
(Sep 2023 – Present)
What is Ran Salomon email address?
Email Ran Salomon at [email protected] and [email protected]. This email is the most updated Ran Salomon's email found in 2026.
How to contact Ran Salomon?
To contact Ran Salomon send an email to [email protected] or [email protected]. (updated on November 23, 2025)
What company does Ran Salomon work for?
Ran Salomon works for Compugen.
What is Ran Salomon's role at Compugen?
Ran Salomon is Associate Director, Antibody Engineering
What industry does Ran Salomon work in?
Ran Salomon works in the Biotechnology industry.
